The FDA has granted a breakthrough therapy designation to the investigational MET inhibitor tepotinib as a treatment for patients with metastatic non–small cell lung cancer (NSCLC) with MET
ex14) alterations who have progressed on prior platinum-based chemotherapy.1
ex14 mutations by the Japanese Ministry of Health, Labor and Welfare.
- Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations. Merck KGaA. Published September 11, 2019. https://prn.to/2kuDROO. Accessed September 11, 2019.
- Pain PK, Veillon R, Cortot AB, et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. J Clin Oncol. 2019;37 (suppl; abstr 9005). doi: 10.1200/JCO.2019.37.15_suppl.9005.
... to read the full story